Press Release Oct 31 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the acquisition of the UK-based LiqMeds Group through its subsidiary Zydus Pharmaceuticals UK Limited. The acquisition focuses on the development and supply of oral liquid products for global markets, with an upfront payment involved. This transaction is expected to be accretive to earnings per share from the first year of acquisition. The Managing Director emphasized the growth potential in the oral liquids market, particularly for geriatric and pediatric patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 30 2023
- Press Release Oct 25 2023
- Press Release Oct 20 2023
- Press Release Oct 16 2023
- Press Release Oct 06 2023
Later from Zydus Lifesciences
- Press Release Nov 02 2023
- Press Release Nov 03 2023
- Zydus Lifesciences Limited Press Release Nov 06 2023
- Press Release Nov 07 2023
- Press Release Nov 10 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences